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A significant frequency of mutations (six missense and one silent) was found, for the first time, at the coding region of the bak gene
(exons 3, 4 and 6) in 42 carcinomas of the uterine cervix, while no mutations were detected in 32 non-neoplastic cervix tissues. Bak
mutations were observed more frequently in the advanced stage and mutated cancer tissues were more resistant to radiotherapy,
although trends were not statistically significant because of small sample size.
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Carcinoma of the uterine cervix remains the fifth most common
female neoplasm worldwide. It appears that an early event is
infection by human papilloma viruses (HPV) (Lorincz et al, 1987).
However, not all patients with HPV infection develop invasive
cancer, implying that additional molecular alterations may
contribute to the multistep carcinogenesis process. These altera-
tions most probably include activation of oncogenes or inactiva-
tion of tumour suppressor genes.
The bak gene, a recently identified member of the Bcl-2 family of
apoptosis regulatory genes, has been shown to function as a potent
inducer of apoptosis (Chittenden et al, 1995b; Kiefer et al, 1995). It
has been mapped to the chromosome 6 p 21.3 (Herberg et al,
1998). A high incidence of loss of heterozygosity was found
at this region in human cervical cancer (Kersemaekers et al,
1998), suggesting the involvement of a tumour suppressor gene.
Since transformation of the cervical epithelial tissue to carcinoma
is associated with the progressive inhibition of apoptosis (Nair
et al, 1999) and bak-mediated apoptosis occurs in these cells
(Krajewski et al, 1996), abrogation of this bak-mediated apoptosis
could lead to transformation of the cervical epithelium. The bak
gene may be acting as a tumour suppressor gene in cervical
carcinoma.
We, therefore, studied the potential role of the bak gene as a
tumour suppressor gene in cervical carcinoma by analysing the
coding region for the presence of mutations and assessed its
relation to the response to radiotherapy.
PATIENTS AND METHODS
Cervix cancer cases and radiotherapy
Biopsied specimens from 42 patients with cervical carcinoma were
obtained with informed consent prior to the initiation of radio-
therapy at the Nanavati Hospital. The average age of the patients at
biopsy was 51.673.9 years (mean 7 95% CI). Patients were
classified as 12 stage II cases and 30 stage III cases according to the
criteria defined by the Federation of Gynecologists and Oncolo-
gists. All patients were irradiated with 60Co g-rays by Theratron
780C (Atomic Energy of Canada Ltd, Chalk River, ON, Canada), a
telecobalt equipment. Patients were treated at a dose rate of
1.2–1.4Gymin 1 with a parallel opposed field, box technique or
with multiple beams to encompass the entire pelvic disease. The
upper margin of the field was placed at the L5/S1 junction, whereas
the lower margin included the lowest palpable disease with a
centimetre of margin. All patients received 50Gy in 5 weeks with
conventional fractionation (2Gy daily for 5 weeks with no
radiation on Saturday and Sunday). A boost with brachytherapy
or with reduced field of external radiation was delivered after a gap
of 8–10 days of external radiation. A minimum of 70Gy was
delivered with a maximum dose of 74Gy (Huilgol et al, 1988).
Patients were assessed for response within a week of conclusion of
irradiation. The initial response as assessed clinically was
categorised as complete or partial by the WHO criterion (WHO,
1979). Briefly, complete response is defined as complete regression
of clinically detectable tumour, while partial is anything less than
complete response but more than 50% of the initial tumour burden
(Huilgol and Chatterjee, 1996).
Serial paraffin sections (5mm thickness) were made and stained
with haematoxylin and eosin. Following the microscopic view,
parts of unstained paraffin sections containing tumour tissues
were scraped using a sterile surgical blade under the microscope
and used for DNA extraction. As controls, paraffin sections of non-
neoplastic cervical tissue specimens taken from 32 patients
undergoing hysterectomy at Nanavati Hospital for various Received 3 July 2002; revised 2 January 2003; accepted 5 March 2003
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snon-neoplastic uterine diseases (30 chronic endocervicitis tissues
and two normal cervix tissues from endometroid adenocarcinoma
patients) were examined. The average age of the patients was
44.973.8 years (mean 795% CI).
Examination of bak mutation
PCR amplification followed by SSCP analysis and direct sequen-
cing was carried out to detect mutations. Briefly, DNA was
extracted from microdissected paraffin-embedded sections using
the DNeasy tissue kit (QIAGEN Inc., Valencia, CA, USA), and
exons 3, 4 and 6 of the bak gene were amplified by PCR (Geneamp
PCR system 9700; Perkin-Elmer, Norwalk, CA, USA). The primer
pairs used for PCR amplification were 50-TGCCTCCCTGAA-
GATGTCCT-30 and 50-TGACTCCCAGCTTTGATCCT-30 for exon
3, 50-GGCAGGGTATGGTATGGTTG-30 and 50-TCCCGACTGC-
CTGGTTACTG-30 for exon 4, and 50-GCAAGGGAACAGAGAAGG-
CA-30 and 50-TGACCACCTTGTTTCTCCCG-30 for exon 6 as
reported previously (Kondo et al, 2000). PCR products were
subjected to SSCP without radioisotopes (cold-SSCP) (Hongyo
et al, 1993). The optimal temperatures for electrophoresis were
251C for exons 3 and 6 and 201C for exon 4. The SSCP bands,
which showed altered mobility as compared to the wild-type
control (human lymphocyte DNA), were extracted from the gel
and reamplified by PCR to enrich the mutated alleles (Figure 1A).
The mutated alleles were purified using the QIAquick PCR
purification kit (QIAGEN Inc.). Direct sequencing was performed
by the dideoxy chain termination method using the Big Dye
Terminator cycle sequencing kit (Perkin-Elmer) and the auto-
mated DNA sequencer (ABI prism 3100 genetic analyser; Perkin-
Elmer) (Figure 1B). The same primers were used for both PCR and
direct sequencing. DNA extraction, PCR–SSCP analysis and
sequencing of the mutated alleles were repeated more than twice
to rule out the possibility of contamination and artifacts.
Statistical analysis was carried out by the SPSS statistical system
(SPSS Inc., Chicago, IL, USA).
RESULTS AND DISCUSSION
Six transition type mutations and one silent mutation of the bak
gene were observed in 42 cervical cancer specimens (Table 1). Four
mutations were found in exon 3 of the bak gene in three cases: two
in exon 4 in two cases and one in exon 6 in one case. One case
showed a double mutation in exon 3. No sequence alterations were
found in any of the 32 non-neoplastic cervical tissues. We have, for
the first time, shown a significant increase of mutations in the
functional domain of the bak gene in human cervical carcinoma. In
this study, mutations in the bak gene occurred more frequently in
advanced-stage tumours (16.7% in stage III vs 8.3% in stage II),
although the difference was not statistically significant. It may be a
late event in cervical carcinogenesis. This is in agreement with
studies of the bak gene in gastric and colorectal cancers where
most of the mutations occurred at advanced stage (Kondo et al,
2000). Furthermore, cervical cancer tissues with bak mutations
showed a decreased response to radiotherapy in comparison to
those without bak mutation (Table 2). However, the difference was
not statistically significant because of the small sample size
(P¼0.12).
Bak, which is a member of the Bcl-2 family, shows the presence
of the BH1, BH2 and BH3 homology domains and a membrane-
anchoring region (Chittenden et al, 1995a). The bak gene functions
by binding and inhibiting the antiapoptotic molecule Bcl-xL,
thereby inducing apoptosis. The BH3 domain of the bak gene,
encoded by exon 4, has been shown to be responsible for its ability
to induce apoptosis as well as bind Bcl-xL (Chittenden et al, 1995a),
while constructs lacking exon 3 did not influence the cytotoxicity
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Figure 1 Detection of bak mutations in cervical carcinoma by cold-SSCP
and direct sequencing. (A) Cold-SSCP profiles. PCR products from tumour
DNA were run alongside a wild-type (WT) control (human lymphocyte
DNA). Bands showing altered mobility were observed in six cervical cancer
cases (M17, 28, 34 for exon 3, M21, 31 for exon 4 and M38 for exon 6).
(B) Sequencing profiles of the bands showing altered mobility on the SSCP
gel. Arrows indicate the bases altered from wild type to mutant type.
Table 1 Mutations in coding region of the bak gene in cervical carcinoma
Mutations at
Stage No. of cases Cases with mutation exon 3 exon 4 exon 6
Cancerous tissues II 12 1 1
a 00




Total – 42 6
e 421
Non-neoplastic tissues – 32 0 0 0 0
aCodon 60 (ATG-GTG: Met-Val).
bCodon 30 (GAC-AAC: Asp-Asn)+codon 57 (GAC-AAC: Asp-Asn),
codon 59 (GAG-GAA: Glu-Glu).
cCodon 74 (GTG-ATG: Val-Met), codon 80 (ATC-ACC: Ileu-Thr).
dCodon
191 (GTG-GCG: Val-Ala).
ePo0.05 vs control by Fisher’s exact test.
bak mutation in human cervical cancer
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sof bak in Rat-1 cells. Deletion of the membrane-anchoring region
of the bak gene, located in exon 6, was found to reduce its
cytotoxicity because of altered subcellular localisation. We have
identified missense mutations in the BH3 domain in two speci-
mens and mutation in the membrane-anchoring region in one
specimen. Since these mutations occurred in domains responsible
for Bcl-xL binding and subcellular localisation, it is likely that these
mutations resulted in loss of proapoptotic function of the bak gene
in these specimens and caused the reduced response to radio-
therapy. In two cervical cancer tissues, however, missence
mutations were found in exon 3. Further study is required to
know the contribution of mutations in exon 3 to cervical
carcinogenesis.
The bak gene has been shown to induce apoptosis in a p53-
independent manner in lung cancer cell lines (Pataer et al, 2000).
In most cervical carcinomas, p53 is nonfunctional either because of
HPV infection or because of mutations in the p53 gene (Lazo,
1999). In the absence of functional p53, bak-mediated apoptosis
may occur in the cervical epithelium. Abrogation of this bak-
mediated apoptosis could lead to the development of cervical
carcinomas at least in a subset of cases and results in the reduced
response to radiotherapy.
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a No. of cases Partial Complete
+4 3
c 1
  26 8 18
aMissense mutations detected in the biopsied specimens taken prior to radiotherapy.
bWHO criterion (9, 10).
cP¼0.12 by Fisher’s exact test.
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